{"id":754943,"date":"2023-05-04T09:57:49","date_gmt":"2023-05-04T13:57:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/"},"modified":"2023-05-04T09:57:49","modified_gmt":"2023-05-04T13:57:49","slug":"spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/","title":{"rendered":"Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CAMBRIDGE, Mass., May  04, 2023  (GLOBE NEWSWIRE) &#8212; Spero Therapeutics, Inc.\u00a0(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Thursday, May 11, 2023 at 4:30 p.m. ET to report its first quarter 2023 financial results and provide an update on its business and pipeline.<\/p>\n<p align=\"justify\">To access the call, please dial 1-855-327-6837 (domestic) or 1-631-891-4304 (international) and refer to conference ID 10021779, or click on this <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=P8T7fs7BOH-c_fcyAj7ALD3jLKncpP4Ce3ZwtghB1Jwnpr6RVbHHxBryaXdG3aI4N9TJPFAr3N9lC3MjxRie7bTpdFdgYXO61mwNTn1er_HX8y5E40aqyjWXtqvQIzEc48i-NE12DOe8slY0uQTSObIKXSQw7X3mOhy8Nu5INOogDZKXG472vWjw3K5V1o8E\" rel=\"nofollow noopener\" target=\"_blank\"><strong><em><u>link<\/u><\/em><\/strong><\/a> and request a return call. The audio webcast can be accessed on the &#8220;Events and Presentations&#8221; page under the \u201cConnect\u201d tab of the Company&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7Ta85epp9gaepQMcVDY4BP3oMk0LQv16vJdEMOL4wzDMDncd6hsmG-nHYD6athUECDExXIo9Vdlc_h_0KdYPDdOfEapFnhDlrF7Low1-pEc=\" rel=\"nofollow noopener\" target=\"_blank\"><strong><em><u>www.sperotherapeutics.com<\/u><\/em><\/strong><\/a>. The archived webcast will also be available on Spero&#8217;s website for 30 days following the call.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0Spero<\/strong>\u00a0<strong>Therapeutics<\/strong><br \/>Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including multi-drug resistant bacterial infections and rare diseases.<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Spero Therapeutics is developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.\n<\/li>\n<li style=\"text-align:justify\">Tebipenem HBr is an investigational drug in the United States being developed for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis, caused by certain bacteria, in adult patients who have limited treatment options; tebipenem HBr is not U.S. Food and Drug Administration (FDA)-approved.\n<\/li>\n<li style=\"text-align:justify\">Spero Therapeutics also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is in development to treat MDR Gram-negative infections in the hospital setting.<\/li>\n<\/ul>\n<p align=\"justify\">For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=73Wr7Elxe2zwJGijXCYViKF6xyCiEqeF3sie7I4EpekQ3S_pptvJi2QQ7khQ9llCephJ0X4DK9kzTHg2LYIHOXDO-VR7oQ4oq3-L67zLQ5M=\" rel=\"nofollow noopener\" target=\"_blank\"><strong><em><u>https:\/\/sperotherapeutics.com<\/u><\/em><\/strong><\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>Ted Jenkins<br \/>Vice President, Investor Relations and Strategic Finance<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LpnMP86sF5HgU4_qSlAm-6y_KBX6UsVoDQG36pgz3rtPtskB0o42tH0JGDJRH961D-AhHEe7JMg3HIjDR_7EgfqugH-nDMxt2SodpIKqpdI=\" rel=\"nofollow noopener\" target=\"_blank\">IR@sperotherapeutics.com<\/a><br \/>(617) 798-4039<\/p>\n<p align=\"justify\">\n        <strong>Media Inquiries:<\/strong><br \/>\n        <br \/>Lora Grassilli, Health Media Relations<br \/>Zeno Group<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j5LMQAzmQt83ZU5D00xhAxWViTwxQdpYckGPW06jF8a1QBNohL0LeHUs4vHToCsxdCO7Vs5gJXZ1Jad10zjhfQ5YviVe9q618urz5LOXu21aNcv7Q5UD9ycHnmE-zelU\" rel=\"nofollow noopener\" target=\"_blank\">lora.grassilli@zenogroup.com<\/a><br \/>646-932-3735<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQ4MCM1NTczMTgyIzIwOTAzNjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MTBjMTM2NGQtNzY4Yy00YzllLTg0YzgtNjRmZTgzOGRiNjVmLTExMDE5MzM=\/tiny\/Spero-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) &#8212; Spero Therapeutics, Inc.\u00a0(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Thursday, May 11, 2023 at 4:30 p.m. ET to report its first quarter 2023 financial results and provide an update on its business and pipeline. To access the call, please dial 1-855-327-6837 (domestic) or 1-631-891-4304 (international) and refer to conference ID 10021779, or click on this link and request a return call. The audio webcast can be accessed on the &#8220;Events and Presentations&#8221; page under the \u201cConnect\u201d tab &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-754943","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) &#8212; Spero Therapeutics, Inc.\u00a0(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Thursday, May 11, 2023 at 4:30 p.m. ET to report its first quarter 2023 financial results and provide an update on its business and pipeline. To access the call, please dial 1-855-327-6837 (domestic) or 1-631-891-4304 (international) and refer to conference ID 10021779, or click on this link and request a return call. The audio webcast can be accessed on the &#8220;Events and Presentations&#8221; page under the \u201cConnect\u201d tab &hellip; Continue reading &quot;Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-04T13:57:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQ4MCM1NTczMTgyIzIwOTAzNjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023\",\"datePublished\":\"2023-05-04T13:57:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\\\/\"},\"wordCount\":329,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTQ4MCM1NTczMTgyIzIwOTAzNjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\\\/\",\"name\":\"Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTQ4MCM1NTczMTgyIzIwOTAzNjI=\",\"datePublished\":\"2023-05-04T13:57:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTQ4MCM1NTczMTgyIzIwOTAzNjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTQ4MCM1NTczMTgyIzIwOTAzNjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/","og_locale":"en_US","og_type":"article","og_title":"Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 - Market Newsdesk","og_description":"CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) &#8212; Spero Therapeutics, Inc.\u00a0(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Thursday, May 11, 2023 at 4:30 p.m. ET to report its first quarter 2023 financial results and provide an update on its business and pipeline. To access the call, please dial 1-855-327-6837 (domestic) or 1-631-891-4304 (international) and refer to conference ID 10021779, or click on this link and request a return call. The audio webcast can be accessed on the &#8220;Events and Presentations&#8221; page under the \u201cConnect\u201d tab &hellip; Continue reading \"Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-04T13:57:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQ4MCM1NTczMTgyIzIwOTAzNjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023","datePublished":"2023-05-04T13:57:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/"},"wordCount":329,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQ4MCM1NTczMTgyIzIwOTAzNjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/","name":"Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQ4MCM1NTczMTgyIzIwOTAzNjI=","datePublished":"2023-05-04T13:57:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQ4MCM1NTczMTgyIzIwOTAzNjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQ4MCM1NTczMTgyIzIwOTAzNjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754943","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=754943"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754943\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=754943"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=754943"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=754943"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}